Atrial fibrillation for internists: current practice.


Journal

Swiss medical weekly
ISSN: 1424-3997
Titre abrégé: Swiss Med Wkly
Pays: Switzerland
ID NLM: 100970884

Informations de publication

Date de publication:
09 03 2020
Historique:
entrez: 23 3 2020
pubmed: 23 3 2020
medline: 19 8 2021
Statut: epublish

Résumé

Atrial fibrillation (AF) has become a global epidemic and puts affected patients at high risk of adverse events. In this review we summarise the current evidence on risk factors and complications of AF, describe current treatment strategies, and outline new fields of research. Current evidence shows that hypertension and obesity are the two most important modifiable risk factors for the development of AF. Patients with AF face an increased stroke risk. Oral anticoagulation reduces this risk substantially. Mainly for reasons of safety and ease of use, non-vitamin K antagonist oral anticoagulants are preferred for stroke prevention. Rate and rhythm control interventions remain important and are mainly used for symptom control in AF patients. Rate control is recommended as an initial treatment and in patients with a low or absent symptom burden. Following the advent of AF ablation 20 years ago, the chances of successful sustained rhythm control have increased. Nevertheless, the procedural risks, although low, must be discussed with the patient in the context of the potential benefits. Heart failure and AF often coexist, which creates a further challenge for optimal AF management. Recent studies have shown that AF patients have a high burden of silent brain lesions, and that these lesions are associated with cognitive dysfunction. A better understanding of these interrelationships may eventually help the development of new prevention and treatment strategies to decrease the burden and complications associated with AF.

Identifiants

pubmed: 32200547
doi: 10.4414/smw.2020.20196
pii: Swiss Med Wkly. 2020;150:w20196
doi:
pii:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

w20196

Auteurs

Pascal Meyre (P)

Division of Cardiology, Department of Medicine, University Hospital Basel, Switzerland / Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland.

David Conen (D)

Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland / Population Health Research Institute, Hamilton, Ontario, Canada.

Stefan Osswald (S)

Division of Cardiology, Department of Medicine, University Hospital Basel, Switzerland / Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland.

Michael Kühne (M)

Division of Cardiology, Department of Medicine, University Hospital Basel, Switzerland / Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland.

Christine Meyer-Zürn (C)

Division of Cardiology, Department of Medicine, University Hospital Basel, Switzerland / Cardiovascular Research Institute Basel, University Hospital Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH